Loading...
XASXBGT
Market cap4mUSD
Dec 20, Last price  
0.04AUD
Name

Bio-Gene Technology Ltd

Chart & Performance

D1W1MN
XASX:BGT chart
P/E
—
P/S
428.66
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
9.55%
Rev. gr., 5y
-48.56%
Revenues
18k
-96.92%
760186,4156,316344,450508,758907,580573,119879,776595,07818,320
Net income
-2m
L-22.18%
-87,306-98,261-322,518-1,054,902-2,833,050-1,919,723-1,869,851-2,358,150-2,801,987-3,095,782-2,409,179
CFO
-3m
L-15.94%
-47,567-126,950-419,345-729,152-2,373,454-2,201,479-1,644,691-1,825,52243,515-3,276,354-2,754,245
Earnings
Feb 24, 2025

Profile

Bio-Gene Technology Limited, an agtech development company, engages in developing and commercializing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. Its lead products include Flavocide, a beta-triketone insecticide product; and Qcide, a natural oil extracted from a cultivar of eucalyptus cloeziana. The company has a research collaboration agreement with James Cook University for the development of a tissue culture system to support the expansion of tree plantations and scale-up of future Qcide oil production. It also has research collaborations with BASF, Grains Research and Development Corporation, and Queensland Department of Agriculture and Fisheries for assessing activity against grain storage pests. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.
URL
https://bio-gene.com.au/
IPO date
Nov 29, 2017
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
18
-96.92%
595
-32.36%
880
53.51%
Cost of revenue
3,081
3,077
3,103
Unusual Expense (Income)
NOPBT
(3,062)
(2,482)
(2,224)
NOPBT Margin
Operating Taxes
(604)
(86)
(112)
Tax Rate
NOPAT
(2,458)
(2,396)
(2,111)
Net income
(2,409)
-22.18%
(3,096)
10.49%
(2,802)
18.82%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,979
4,483
BB yield
-21.73%
-22.49%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
23
40
25
Net debt
(2,210)
(2,991)
(6,342)
Cash flow
Cash from operating activities
(2,754)
(3,276)
44
CAPEX
(6)
(7)
Cash from investing activities
(6)
(7)
Cash from financing activities
1,979
(75)
4,408
FCF
(2,758)
(2,474)
(1,974)
Balance
Cash
2,210
2,991
6,342
Long term investments
Excess cash
2,209
2,961
6,298
Stockholders' equity
2,791
3,221
6,268
Invested Capital
605
301
25
ROIC
ROCE
EV
Common stock shares outstanding
185,818
167,768
153,338
Price
0.05
-37.18%
0.08
-40.00%
0.13
-23.53%
Market cap
9,105
-30.42%
13,086
-34.35%
19,934
-14.56%
EV
6,896
10,095
13,592
EBITDA
(3,024)
(2,436)
(2,180)
EV/EBITDA
Interest
53
Interest/NOPBT